Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$31.02B+47.56%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas Schinecker
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 103,249
- Beta
- 0.35
- Country
- CH
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 5.66
Financials
Revenue
$31.02B+47.6%Net Income
$7.02B+112.4%EBITDA
$9.64B+15.6%Free Cash Flow
$5.72B+85.3%EPS (diluted)
$1.09+131.9%Shares Outstanding (diluted)
6.47B-6.1%Operating Expenses
$14.33BCash & Debt
$9.70BReturn of Capital
$8.56BDividend per Share
$1.55Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $63.36B | $12.88B | $2.02 |
| 2024 | $62.40B | $8.28B | $1.30 |
| 2023 | $60.44B | $11.50B | $1.80 |
| 2022 | $65.81B | $12.42B | $1.94 |
| 2021 | $62.80B | $13.93B | $2.05 |
| 2020 | $58.32B | $14.29B | $2.09 |
| 2019 | $63.75B | $13.50B | $1.97 |
| 2018 | $59.50B | $10.50B | $1.54 |
| 2017 | $55.75B | $8.63B | $1.26 |
| 2016 | $52.64B | $9.58B | $1.41 |
| 2015 | $50.40B | $8.86B | $1.30 |
| 2014 | $49.87B | $9.33B | $1.37 |
| 2013 | $48.61B | $11.16B | $1.62 |
| 2012 | $47.44B | $9.54B | $1.39 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from RHHBY's reported EPS growth of 2.9% a year over 13 years.
- EPS in 5 years
- $2.31
- Implied price
- $46.27
- Return from $52.25
- -2.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $23.01 — -56.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -7.1% | -18.0% | -14.7% | -11.9% | -9.4% | -7.1% |
| -2.1% | -13.5% | -10.1% | -7.1% | -4.5% | -2.1% |
| 2.9% | -9.1% | -5.5% | -2.4% | 0.4% | 2.9% |
| 7.9% | -4.7% | -0.9% | 2.3% | 5.2% | 7.9% |
| 12.9% | -0.3% | 3.7% | 7.1% | 10.1% | 12.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+7.69%Social Signal Score
Mentions (23)
- Newsseekingalpha.com·7d ago·Negative
Roche Holding AG (RHHBY) Discusses Pharma Strategy, R&D Excellence, AI in Drug Development, and Pipeline Updates Across Key Therapeutic Areas Transcript Roche Holding AG (RHHBY) Discusses Pharma Strategy, R&D Excellence, AI in Drug Development, and Pipeline Updates Across Key Therapeutic Areas Transcript
View source ↗ - Newsreuters.com·8d ago·Neutral
Roche outlines plans to move towards autonomous AI labs Swiss pharmaceutical giant Roche outlined plans to move towards autonomous AI labs to speed up research and development discovery at its pharma investor day on Monday.
View source ↗ - Newsreuters.com·12d ago·Negative
Roche signs drug-discovery deal with Atavistik Bio worth up to $2 billion Drug developer Atavistik Bio said on Thursday it has signed a deal with Swiss drugmaker Roche potentially worth nearly $2 billion, including milestone payments, to develop oral treatments for cardiovascular, kidney and metabolic diseases.
View source ↗ - Newsseekingalpha.com·12d ago·Neutral
… GLP-1 Player Roche is poised to become a top player in the obesity/weight loss market, challenging Eli Lilly and Novo Nordisk with its robust pipeline. Enicepatide, RHHBY's GLP-1/GIP agonist, demonstrated competitive Phase 2 efficacy and safety, with 15.5% weight loss and 2.65% HbA1c reduction at 48 weeks in T2D patients. RHHBY's diversified portfolio, strong margins, and minimal patent cliffs underpin its blue-chip status, while the obesity franchise offers substantial upside potential.
View source ↗ - Newsbenzinga.com·13d ago·Neutral
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and licensing partner Roche Holdings AG (OTC:RHHBY) on Wednesday shared prespecified interim outcomes from their ongoing Phase 3 IMAgINATION trial of investigational sefaxersen in adults diagnosed with primary IgA nephropathy (IgAN).
View source ↗ - Newswsj.com·13d ago·Negative
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease The company said it would share the study's interim data with health authorities with the aim of bringing the treatment to the market as soon as possible.
View source ↗ - Newsreuters.com·13d ago·Neutral
Roche proposes former Takeda CEO for board seat Roche on Wednesday said it was proposing Christoph Weber, the former CEO of Takeda Pharmaceuticals , for election to the Swiss company's board of directors at its AGM next March.
View source ↗ - Newsbusinesswire.com·13d ago·Neutral
Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN) CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner Roche today announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningfu
View source ↗ - Newszacks.com·13d ago·Negative
Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study RHHBY's enicepatide cut HbA1c and body weight in a phase II study, strengthening its obesity ambitions as it advances the drug into phase III.
View source ↗ - Newsreuters.com·14d ago·Negative
Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial Swiss drugmaker Roche said on Tuesday its experimental dual-acting obesity drug helped overweight or obese patients with type 2 diabetes lower blood sugar levels and lose an average 15.5% of their body weight in a mid-stage trial.
View source ↗ - Newswsj.com·14d ago·Negative
Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial The results for enicepatide reinforce the company's ambitions to rapidly develop its portfolio of medicines for people with obesity, diabetes and cardiovascular disease.
View source ↗ - Newszacks.com·18d ago·Neutral
RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.
View source ↗ - Newszacks.com·25d ago·Neutral
Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder RHHBY's sBLA for Enspryng wins FDA priority tag for myelin oligodendrocyte glycoprotein antibody-associated disease. A decision is due on Jan. 10, 2027.
View source ↗ - Newsreuters.com·35d ago·Negative
Roche signs global licensing pact for Simcere's experimental blood cancer drug Switzerland's Roche will pay $75 million upfront to Simcere Pharmaceutical Group for rights to an experimental blood cancer drug, the Chinese drugmaker said Tuesday.
View source ↗ - Newsyoutube.com·35d ago·Neutral
U.S.' 'win' in the war has been choking off Iran's oil exports: David Roche David Roche of Quantum Strategy says oil flows out of the Strait of Hormuz are likely to be far lower than what the U.S. claims. He adds that while Washington's economic pressure on Tehran is growing, it's unlikely to change Iran's strategy of wanting to control the Strait of Hormuz.
View source ↗ - Newszacks.com·39d ago·Neutral
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
View source ↗ - Newsseekingalpha.com·42d ago·Neutral
Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case Nurix secures a transformative Roche partnership, gaining $700M upfront, 50% U.S. profit share, and 60% Roche-funded global development for bexobrutideg. NRIX's financial runway is extended to ~3.5 years, reducing near-term dilution risk and enabling multi-indication expansion without sacrificing U.S. economics. Bexobrutideg's Phase 1 data show high response rates in CLL/SLL, with a pivotal Phase 3 trial aiming to demonstrate s
View source ↗ - Newsforbes.com·43d ago·Negative
FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify symptoms related to Alzheimer's disease in patients over age 55, Roche said on Monday morning.
View source ↗ - Newswsj.com·43d ago·Negative
FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed by Roche and Eli Lilly.
View source ↗ - Newsreuters.com·43d ago·Negative
Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of Alzheimer's disease in people aged 55 and older with cognitive decline.
View source ↗ - Newsprnewswire.com·43d ago·Neutral
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patients Quest also launching a new multi-biomarker AD-Detect® lab-developed blood test with low 10% indeterminate rate, so more patients can receive an actionable insight SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information service
View source ↗ - Newsmarketbeat.com·50d ago·Negative
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates Recursion Pharmaceuticals NASDAQ: RXRX is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Taylor said during a BofA Global Research virtual conference.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Roche Is Getting More Benefit Of The Doubt On Improving Execution Roche Holding AG remains a respectable long-term hold, supported by a deep pipeline, strong execution, and robust financial resources. Q2 results showed 5% revenue growth and better-than-expected operating margin, validating management's focus on R&D efficiency and cost control. Key upcoming clinical readouts in oncology, immunology, and hematology could drive meaningful revenue shifts over the next 12–24 months.
View source ↗
Earnings
Thu, Feb 4(in 4 months)
Consensus estimate $1.45 per share
Typical surprise +0.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 23$1.66 vs $1.58beat
- Thu, Jan 29$1.36 vs $1.35beat
- Thu, Jul 24$1.74 vs $1.62beat
- Thu, Jan 30$1.18 vs $1.17beat
- Mon, Jul 22$1.43 vs $1.30beat
- Thu, Feb 1$1.23 vs $1.22beat
Estimates and results for RHHBY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Ritchie Torreshouse · NY15 · disclosed Aug 20, 2025 (40d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed May 14, 2025 (35d later)Sell$1,001 - $15,000
- Bruce Westermanhouse · AR04 · disclosed May 13, 2025 (22d later)Sell$1,001 - $15,000
- Bruce Westermanhouse · AR04 · disclosed Apr 17, 2025 (45d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 15, 2024 (23d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (18d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$50,001 - $100,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jun 11, 2023 (26d later)Sell$1,001 - $15,000
- Dan Meuserhouse · PA09 · disclosed Apr 25, 2023 (29d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (17d later)Buy$1,001 - $15,000
- Dan Meuserhouse · PA09 · disclosed Mar 30, 2023 (30d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Mar 20, 2023 (21d later)Sell$15,001 - $50,000
- Diana Harshbargerhouse · TN01 · disclosed Mar 2, 2023 (36d later)Sell$1,001 - $15,000
- Diana Harshbargerhouse · TN01 · disclosed Mar 2, 2023 (36d later)Sell$1,001 - $15,000
- Diana Harshbargerhouse · TN01 · disclosed Mar 2, 2023 (36d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Feb 24, 2023 (42d later)Buy$15,001 - $50,000
- Dwight Evanshouse · PA03 · disclosed Nov 21, 2022 (7d later)Buy$1,001 - $15,000
- John Henry Rutherfordhouse · FL04 · disclosed Apr 19, 2022 (34d later)Sell$1,001 - $15,000
- Diana Harshbargerhouse · TN01 · disclosed Mar 29, 2022 (22d later)Buy$1,001 - $15,000
- Diana Harshbargerhouse · TN01 · disclosed Feb 28, 2022 (20d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.